Mesoblast has been thrown a lifeline after gaining backing from US-based strategic investor SurgCenter Development via a $US110 million ($138 million) private placement.
The placement of 60 million shares was priced at $2.30 a share, a 6.5 per cent discount to the price on Thursday.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
